Clinical Pharmacokinetics of Cyclophosphamide

Clinical Pharmacokinetics

Volumn 20, Issue 3, 1991, Pages 194-208

  Moore, Malcolm J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; DOSE RESPONSE; DRUG METABOLISM; HEMORRHAGIC CYSTITIS; HUMAN; HYPONATREMIA; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ALDEHYDE DEHYDROGENASE; ANIMAL; CYCLOPHOSPHAMIDE; HUMAN; KIDNEY DISEASES; LIVER DISEASES; NITROIMIDAZOLES; XANTHINES;

EID: 0026100542     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199120030-00002     Document Type: Review

References (91)

1. The effect of allopurinol on cyclophosphamide antitumour activity
2. The effect of phenobarbital on cyclophosphamide antitumour activity
3. Limited sampling model predicts cyclophosphamide area under the curve but not cyclophosphamide metabolite exposure
4. The uptake and metabolism of cyclophosphamide by the ovary
5. Clinical pharmacology of cyclophosphamide
6. Studies of the antidiuretic effect of cyclophosphamide
7. Conceptual and practical advances in the management of breast cancer
8. Dose response effect of adjuvant chemotherapy in breast cancer
9. Allopurinol and cytotoxic drugs
10. Nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites
11. The disposition of cyclophosphamide in a group of myeloma patients
12. The oxazaphosphorines
13. High dose cyclophosphamide therapy for malignant disease
14. Rapid method for detection of ifosfamide and cyclophosphamide in plasma by high-performance liquid chromatography with solid phase extraction
15. Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents
16. Radiation and chemotherapy sensitizers
17. Alkylating properties of phosphoramide mustard
18. Alkylating agents
19. Observations on the differential metabolism and biological activity of the optical isomers of cyclophosphamide
20. The CMF regimen. Modulation of cyclophosphamide uptake and clearance by methotrexate and fluorouracil
21. Decreased half-life of cyclophosphamide in patients under continual treatment
22. Biliary elimination of cyclophosphamide in man
23. Interaction of cimetidine but not ranitidine with cyclophosphamide in mice
24. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide
25. Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy
26. A limited sampling strategy for cyclophosphamide pharmacokinetics
27. Cyclophosphamide plasma and CSF kinetics with and without dimethyl sulfoxide
28. Improved analysis of cyclophosphamide by capillary gas chromatography with thermionic specific detection and silica sample purification
29. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs
30. Cytotoxic, cell cycle and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents
31. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa
32. Drug resistance and DNA repair
33. Preclinical studies and clinical correlation of the effect of alkylating dose
34. Acute toxicity resulting from combination therapy with cyclophosphamide and BSO
35. Correlation between the cytotoxicity of melphalan and DNA crosslinks as detected by the ethidium bromide fluorescence assay
36. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial
37. Clinical pharmacokinetics of cyclophosphamide
38. Clinical pharmacokinetics of cyclophosphamide
39. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients
40. Combined thin layer chromatography-photography densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites
41. High-performance liquid chromatography of cyclophosphamide in serum
42. Analysis of phosphoramide mustard by reversed-phase ion pair high pressure liquid chromatography
43. Role of aldehyde dehydrogenase in cyclophosphamide resistant L1210 leukemia
44. The problem of oncostatic specificity of cyclophosphamide
45. Stereoselective pharmacokinetics and metabolism of the enantiomers of cyclophosphamide
46. Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression
47. Analysis of 4-hydroxycyclophosphamide by gas chromatography-mass spectrometry in plasma
48. Effect of liver failure on the pharmacokinetics of cyclophosphamide
49. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration
50. The kinetics of salivary elimination of cyclophosphamide in man
51. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide
52. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells
53. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines
54. 4-hydroperoxycyclophosphamide, a model for eliminating residual human tumour cells and T-lymphocytes from the bone marrow graft
55. Chemotherapy during pregnancy
56. The thrombogenic effect of anti-cancer drug therapy in women with stage II breast cancer
57. Phase I trial of GM-CSF plus high dose cyclophosphamide in solid tumors
58. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide
59. Phase I study of continuous infusion cyclophosphamide for protracted durations
60. Aldehyde dehydrogenase catalyzed bioinactivation of cyclophosphamide
61. Analytical and preparative HPLC separation of the enantiomers of ifosfamide, cyclophosphamide and trofosfamide and their determination in plasma
62. Untersuchungen zur Ausscheidung alkylierender Cyclophosphamid Metabolite im Urin von Tumor Patienten
63. Bioavailability of cyclophosphamide following oral administration in high doses
64. Rapid development of enhanced clearance after high-dose cyclophosphamide
65. Multidrug resistance
66. Mixed function oxidase activities of established human colon carcinoma cell lines in the inactivation of cyclophosphamide
67. The metabolism of cyclophosphamide
68. Cancer of the urinary bladder after treatment with cyclophosphamide for non-Hodgkins lymphoma
69. Thromboembolic complications related to chemotherapy in a randomized trial of tamoxifen versus tamoxifen plus chemotherapy
70. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients
71. Liquid Chromatographic determination of cyclophosphamide enantiomers in plasma by precolumn chiral derivatization
72. Nitrogen mustards in treatment of neoplastic disease
73. The role of eldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide
74. Determination of cyclophosphamide in whole blood and plasma by reverse phase high-performance liquid chromatography
75. Evaluation of the potential of glutathione-S-transferase to catalyze the reaction of phosphor-amide mustard, cyclophosphamide or ifosfamide and glutathione
76. 2-mercaptoethanesulfonate (mesna) versus hyperhydration for the prevention of cyclophosphamide induced hemorrhagic cystitis in bone marrow transplantation
77. Effect of drug treatment for lymphoma on male reproductive capacity
78. Metabolism of oxazaphosphorines
79. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase in cultured oxazaphosphorine resistant L1210 and P388 cell lines
80. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation
81. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial
82. Effect of the antiulcer drug ranitidine on the pharmacokinetics and hematologic toxicity of cyclophosphamide and its cytotoxic metabolites
83. Urinary metabolites of the antitumor agent cyclophosphamide
84. Isolation and mass spectral identification of blood metabolites of cyclophosphamide
85. A randomized trial of two dose levels of cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy for patients with metastatic breast cancer
86. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by 5 day continuous infusion
87. Risk of second cancers after treatment for Hodgkin’s disease
88. Phase I clinical and pharmacokinetic trial of SR-2508 and cyclophosphamide
89. Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations
90. Cyclophosphamide, cholinesterase and anaesthesia
91. Clearance and recovery calculations in hemodialysis: application to plasma, red blood cell, and dialysate measurements for cyclophosphamide